Table 3: Analysis of clinical events.

Outcomes (comparisons) Treatment group (n/N) Control group (n/N) RR 95% CI (1) All-cause mortality Xuezhikang capsule and conventional therapy versus placebo and conventional therapy CCSPS 2005 [4] 126/2429 189/2441 0.67 (2) Mortality of CHD (2.1) Xuezhikang capsule and conventional therapy versus placebo and conventional therapy CCSPS 2005 [4] 134/2441 0.69 (2.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy Guan 2010 [22] 6/64 0.15 Lou et al. 2008 [28] 1/41 0.95 Overall (FEM, I2 = 13%) 0.26 (2.3) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy Lin et al. 2009 [27] 0.33 (2.4) Xuezhikang and aspirin versus inositol nicotinate and aspirin Wang and Xiao 2000 [32] 0.15 (3) Myocardial infarction (3.1) Xuezhikang and conventional therapy versus placebo and conventional therapy CCSPS 2005 [4] 0.39 (3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy Lou et al. 2008 [28] 0.95 (3.3) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy Lin et al. 2009 [27] 0.2 (4) Revascularization (4.1) Xuezhikang capsule and conventional therapy versus placebo and conventional therapy CCSPS 2005 [4] 0.67 (4.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy Lou et al. 2008 [28] 1.14 (5) Rehospitalization (5.1) Xuezhikang and conventional therapy versus simvastatin and conventional therapy Lou et al 2008 [28] 1.02 (5.2) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy Lin et al. 2009 [27] 0.2